Individuals with mixed dyslipidemia, including high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), have increased risk for coronary events. We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein AI (apoA-I), and TG response to fenofibric acid (FA) monotherapy and in combination with statins.
INTRODUCTION
Mixed dyslipidemia, which occurs frequently in individuals with insulin resistance, such as those with metabolic syndrome, is characterized by elevated triglycerides (TG) and decreased highdensity lipoprotein cholesterol (HDL-C). Genome-wide association studies (GWASs) have demonstrated associations between common genetic variants and interindividual differences in serum TG and HDL-C (1, 2). Rarer genetic variants discovered by DNA sequencing show a larger effect size on the respective quantitative traits (3, 4) . An important potential application of common and rare variants is to improve prediction of individualized response to therapy and personalize therapy based on that information.
Fibrates, including fenofibric acid (FA), increase HDL-C and apolipoprotein A-I (apoA-I) and decrease TG in individuals with mixed dyslipidemia who are at increased risk for coronary heart disease (5-8). FA is a peroxisome proliferator-activated receptor-alpha (PPAR-) agonist, and as such, its effect can be influenced by common and rare variants in genes involved in the PPAR- pathway.
ApoA5 is an important component of TG lipolysis while inhibiting production of very low-density lipoprotein (LDL). Individuals with mutations in the APOA5 gene were found to have high TG. Common single nucleotide polymorphisms (SNPs) in ApoA5 gene region were found to be associated with TG and HDL-C levels (9).
In recent studies, SNPs in the APOA5 gene region were shown to be significantly associated with both HDL-C and TG response to fibrate monotherapy or in combination with statins (10-13). In this study, we examined the association between rare genetic variants in the APOA5 gene region and change in HDL-C, apoA-I, and TG levels in response to FA alone and in combination with statins. We have included the introns, 3 untranslated region (UTR), and by guest, on October 14, 2017 www.jlr.org Downloaded from promoter region of APOA5 as possible regulatory regions that may affect response to PPAR- agonists. We hypothesized that rare genetic variants affect the response of HDL-C, apoA-I, and TG to therapy with FA in individuals with mixed dyslipidemia.
RESULTS
At baseline, plasma concentrations of HDL-C, apoA-I, and TG were not statistically significantly different among the FA + statin, statin monotherapy, and FA monotherapy treatment groups. As expected, there were significant differences between males and females for baseline HLD-C and apoA-1 based on the inclusion criteria (HDL-C<40 for males, HDL-C <50 for females). There were no or borderline differences for baseline TG. Average age and body mass index (BMI) were higher in women compared to men (differences of 2.8-4.5 Kg and 1.1-1.46 kg/m 2 respectively, depending on the treatment group). Although there was a trend towards higher frequency of diabetes in women, this was not statistically significant (Table 1) .
Plasma levels of HDL-C and apoA-I increased and TG decreased in response to therapy in all treatment groups. As expected, the increases in HDL-C and apoA-I were greatest in the FA + statin combination group and least with statin monotherapy. A similar pattern was observed for the decrease in TG following therapy (Table 2) .
Women had better HDL-C response to therapy than men in the groups receiving FA, either alone or in addition to statins, but not in the statin alone treatment group. However, better response for women did not persist for APOA-I therapy response in the FA only group, but did so for the FA + statin group. A possible explanation of the differences in HDL-C response between men and women could be related to the difference in baseline HDL-C and apoA-I; in addition, women had somewhat higher baseline BMIs and were older than men; this may have On the basis of location within the APOA5 gene and, in the case of the exon variants, whether there was an inferred change in the protein amino acid sequence, we classified the rare DNA variants into six classes: APOA5 3UTR, APOA5 intron, APOA5 promoter, APOA5 missense, and APOA5 synonymous rare variants. Only variants with frequency of <0.01 were included in the analysis. Identified rare variants, their genomic location, frequency in our population study, frequency in a public database if ever reported (1000 Genomes, Exome sequencing project, or other database), and number of individuals who carry each variant in our study are detailed in supplemental Table II . A total of 58 rare variants were identified, of which 27 were previously reported in an external database. Allele frequency ranged between 0.0003-0.004. There were eight participants who had two rare variants, and two participants who had three variants.
We used several approaches to analyze potential rare variant associations, because each method may have certain advantages depending on the actual genetic structure of the trait. Pooled analysis of rare genetic variants in the APOA5 promoter demonstrated significant associations with decreases in HDL-C (Table 3) and apoA-I (Table 4) in response to FA therapy, in contrast to the expected increases. The adjusted mean change in HDL-C following FA monotherapy for participants with rare variants was -4.6 mg/dL; for participants without rare variants, the adjusted mean change in HDL-C following FA monotherapy was +6.2 mg/dL.
Comparison of these mean changes using Student's t-test (P<0.0001) or by the fixed-allele frequency threshold method (P=0.0001) showed highly statistically significant differences. Interestingly, all participants in the FA-monotherapy group with rare variants in the APOA5 promoter region had either a decrease or a very small increase in HDL-C in response to therapy (Figure 1 ). For the statin-monotherapy and combination therapy groups, adjusted mean HDL-C changes in response to therapy were not significantly different in participants with versus participants without rare variants in the APOA5 promoter region. A similar pattern was observed for plasma apoA-I response to therapy; the adjusted mean change in apoA-I in response to FA monotherapy was -2.3 mg/dL in participants with rare variants in the APOA5 promoter region versus +11.6 mg/dL in participants without rare variants in the APOA5 promoter region; the difference between these means was borderline statistically significant by Student's t-test (P<0.06) and the fixed allele-frequency threshold method (P=0.056). There were no significant associations between other classes of APOA5 rare variants and HDL-C response to FA therapy.
We detected a significant effect of missense variants in APOA5 on TG response to therapy ( Table 5 ). The adjusted mean change in TG in response to FA + statin therapy was -228 mg/dL in participants with rare missense variants in the APOA5 gene, compared with -143 mg/dL in participants without rare variants in the APOA5; the difference was statistically significant using both the Student's t-test (P=0.002) and fixed allele-frequency threshold method (P=0.004). In the FA-monotherapy treatment group, adjusted mean change in TG was not significantly different between participants with rare missense variants (-167 mg/dL) and those without -102 mg/dL, however, only two participants had rare missense variants in that treatment group. In contrast to the analysis of HDL-C response to therapy, there was no significant association between the adjusted mean change in TG following FA monotherapy and rare variants in the region of the APOA5 promoter ( 
DISCUSSION
In this study, we identified a number of novel rare APOA5 gene promoter variants that were associated with a paradoxical HDL-C response to FA therapy; participants with these variants had either a decrease or no significant change in HDL-C in response to FA monotherapy. A similar pattern was observed for apoA-I response to FA therapy, suggesting that these variants affect the cholesterol content as well as the apolipoprotein component of HDL particle. Thus, it is possible that the rare APOA5 promoter variants identified in this study, which were associated with decreases or no change in HDL-C and apoA-I levels, may actually attenuate the coronary heart disease reduction effect of FA in the mixed dyslipidemia population.
As a PPAR- agonist, FA modulates multiple downstream targets, including lipoprotein lipase, ATP-binding cassette transporter-1, apoA-I, apoA-II, and apoC-III; however, the exact pathway by which PPAR- agonists increase lipoprotein lipase and apoA-I levels is not completely understood (22). A number of studies have examined the effect of missense common SNPs on response to fenofibrate therapy. Lai and colleagues (11) showed an association of a single SNP, rs3135506, in APOA5 with HDL-C and TG response to FA therapy. In our study, a greater reduction in TG was observed for participants who had rare missense variants compared with those who did not in the FA + statin combination therapy group and a trend toward a difference in the FA-monotherapy group.
Our study has a number of limitations. First, it was a clinical trial that included only individuals with mixed dyslipidemia which are estimated to be ~21% of the adult population (23), and this had a considerable effect on the number of participants. However, the study had a specific single gene related hypothesis that was based on preliminary published studies by guest, on October 14, 2017 www.jlr.org Downloaded from describing common SNPs in the APOA5, including SNPs in the promoter region, which were shown to effect fibrate therapy response in multiple studies (10, 11, 18, 24).
In addition, an approach taken in several published studies examining rare variants of quantitative traits was to examine the extremes of the distribution which is expected to be enriched for rare alleles affecting the trait. Similarly, the current study was designed to examine only individuals with elevated TG and low HDL-C, and elevated LDL-C, the mixed dyslipidemia phenotype. These individuals are expected to be enriched for rare variants in genes affecting lipid metabolism including the APOA5 gene region.
Thus, although larger sample size would have been beneficial, for the targeted hypothesis in this study and specific population of mixed dyslipidemia that is a fraction of the adult population enriched for rare variants, the current sample size and study design were able to further support the role of APOA5 gene in fibrate therapy response by showing the role of rare variants in the response to FA therapy.
Another limitation concerns the distribution of the various statin in the statin alone and statin + FA treatment groups which limits the understanding of the specific effects of each statin type and dose. However, our major finding was in the group receiving FA alone which was homogenous with regards to its therapy.
It is important to mention that there was a gradual increase in response to therapy (for levels of HDL-C, apoA-1, and TG) based on the type of therapy (statin alone, combination therapy, FA alone). There was a modest response to statins alone, a much better response to FA alone, and some additional improvement for the statin-FA combination compared to FA alone.
This pattern is in agreement with previous studies examining response to statin and fibrates therapy, suggesting that our study does follow therapy response pattern described in other clinical trials. Thus, although different statins were used, the overall effect was similar to other studies examining statins and their combination with fibrates.
In conclusion, the present study is the first to show that rare variants in the APOA5 gene promoter region are associated with a paradoxical decrease in plasma HDL-C and apoA-I in response to FA therapy, whereas rare missense variants in the APOA5 gene were associated with greater reduction in TG in response to the combination of FA and statin. These findings may be partly responsible for the interindividual differences in response to fibrate therapy and may be associated with the effect of fibrate monotherapy or in combination with statins on coronary outcomes in individuals with mixed dyslipidemia. As sequencing becomes more affordable and available in the clinical setting, rare variants such as those identified in this study may help to personalize fibrate therapy.
METHODS
Study population. Our study population included European-American participants from three concurrent prospective, randomized, double-blind, clinical trials that examined the efficacy of FA. A detailed description of the study design has been published previously (25). Individuals with TG ≥150 mg/dL, HDL-C <40 mg/dL in men or <50 mg/dL in women, and LDL-C ≥130 mg/dL were eligible and were randomized into six groups for each trial: FA monotherapy, lowerdose statin monotherapy, moderate-dose statin monotherapy, higher-dose statin monotherapy, FA + lower-dose statin, and FA + higher-dose statin. FA was given in 135 mg dose in the FA only and statin +FA groups. Each study used a different statin: rosuvastatin, atorvastatin, or simvastatin. In all studies, participants had a 6-week washout period with no lipid-modifying therapy followed by a 12-week treatment period. Lipid measurements were obtained at the Burden tests used in the analyses included fixed allele-frequency threshold, variable allele-frequency threshold, and frequency-weighted approaches (27-29). Computational prediction of functional effects (e.g., PolyPhen scores or conservation scores) was incorporated in those analyses so the variants could be weighted according to their inferred functional importance. For descriptive purposes, participants were classified in a "rare" group if a rare allele was present at any of the variant sites in a studied gene or gene region; otherwise, participants were classified in a "nonrare" group. Descriptive statistics, including sample size, mean, and standard deviation, were calculated for both rare and nonrare groups and were compared by Ttest. Response to therapy was defined as the difference between baseline and post-therapy levels (e.g., HDL-C = final HDL-C -baseline HDL-C). All responses were adjusted for age, sex, and by guest, on October 14, 2017 www.jlr.org Downloaded from baseline lipid or lipoprotein levels. We obtained residuals (e.g., rHDL-C) from the linear regression of HDL-C = sex + age + diabetes status + BMI + baseline HDL-C and baseline TG.
Statistical analyses using either Student's t-test or burden tests were conducted for the adjusted trait difference (e.g., HDL-C), which included the trait's residual and the mean trait difference before and after therapy (e.g., HDL-C = rHDL-C + mean HDL-C). 
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